The Institute of Research in Biomedicine, together with the Josep Carreras Leukemia Research Institute, the Sant Joan de Déu Research Institute, Vall d’Hebron Institute of Oncology and the University of Barcelona, receives ERDF support to acquire cutting-edge technology in the field of proteomics.
Scientist Cristina Mayor-Ruiz joins IRB Barcelona to lead the “Targeted Protein Degradation and Drug Discovery” laboratory.
With this new group, IRB Barcelona now has 27 laboratories and 8 scientific platforms.
Along with the addition of the new laboratory, the Institute is also launching a Drug Screening Unit devoted to drug discovery.
The announcement is made in light of the recent approval of the preliminary draft of the Spanish government’s budget which announces an investment of more than five billion euros in science.
The signatories demand a national pact that includes long-term strategies aimed at promoting frontier science and business innovation.
The document aims to add and provide strategic solutions to the recent Pact for Science and Innovation that the Government has just announced.
Ernest Giralt is one of the founding members of IRB Barcelona and the former Head of the Institute’s Chemistry and Molecular Pharmacology Programme.
His appointment as “Emeritus Professor” will allow him to share his guidance and expertise with the current community of scientists.
The Academia Programme run by ICREA seeks to foster research excellence among professors at public universities in Catalonia.
María Isabel Hernández-Alvarez, IRB Barcelona scientist and Ramón y Cajal researcher at the Department of Biochemistry and Molecular Biomedicine of the Faculty of Biology of the University of Barcelona (UB), has received the Catalan Society of Biology (SCB) award to a 2020 scientific article. This award honors the authors of a scientific publication from 2019 indexed by the Thomson Reuters Web of Science, which has contributed significantly to the advance of science in biology.
The #LeaveABetterWorld campaign is launched to encourage people to leave part of their estate to biomedical research for the benefit of future generations.
To date, the Institute for Research in Biomedicine (IRB Barcelona) has received more than €1.5 M through such donations.
The institute has set up a web page to encourage legacy gifts.
The project led by Manuel Palacín, head of the Amino Acid Transporters and Disease Laboratory, seeks to develop drugs against schizophrenia and stroke.
”la Caixa” Foundation has devoted €18 M to 25 cutting-edge biomedical research projects devoted to diseases with the greatest impact worldwide, such as cardiovascular, neurological, infectious and oncological diseases.
The goal is to train 15 young researchers in the understanding of metastatic processes and their evolution, with the aim to identify therapeutic solutions.
The Evomet consortium is formed by 13 institutions, which include several of the best academic, clinical and industrial centres working in cancer research and metastasis research in Europe.
Awarded in the Innovative Training Networks Marie Skłodowska-Curie Actions call of the European Commission, the Evomet project has received €4 M and will last for four years.
The ERC Proof of Concept grant offers 150,000 euros to fund the development of new drugs against fibrosis within 18 months.
The SENFIB project aims to eliminate senescent cells. These are damaged cells which, if not destroyed by the immune system, can give rise to aging-related diseases such as idiopathic pulmonary fibrosis and chronic kidney disease.
To achieve this aim, the project makes use of senolytics, molecules which lead to the selective death of these cells and have produced positive results in animal models.